Form 4: Moleculin Biotech CFO Jonathan P. Foster Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Jonathan P. Foster, CFO of Moleculin Biotech, reported the acquisition and disposal of common stock and restricted stock units on June 16, 2024.
Summary
- On June 16, 2024, Jonathan P. Foster, the Chief Financial Officer of Moleculin Biotech, Inc., reported changes in his beneficial ownership of the company's securities.
- Foster acquired 834 shares of common stock through the vesting of restricted stock units.
- He also disposed of 196 shares of common stock to cover tax obligations related to the vesting of these units at a price of $4.14 per share.
- Following these transactions, Foster directly owns 6,011 shares of common stock and 71,878 restricted stock units.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotech industry.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects changes in executive stock ownership.
Key Dates
| Date | Description |
|---|---|
| 06/16/2021 | Reporting person was granted 3,334 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 06/16/2024 | Date of transaction: acquisition of 834 shares of common stock and disposal of 196 shares for tax obligations. |
| 06/18/2024 | Date of signature for the Form 4 filing. |
Keywords
Moleculin Biotech, MBRX, Form 4, Beneficial Ownership, Jonathan P. Foster, CFO, Restricted Stock Units, Common Stock, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.